College of Pharmacy and Gachon Institute of Pharmaceutical Sciences, Gachon University, Incheon, 21936, Republic of Korea.
Department of Chemical Engineering, Dong-Eui University, Busan, 47340, Republic of Korea.
Theranostics. 2024 Oct 14;14(17):6708-6725. doi: 10.7150/thno.100986. eCollection 2024.
Recent studies have demonstrated the direct connections between the skull bone marrow, meninges, and brain. In an effort to explore these connections for the purpose of brain drug delivery, we previously proposed the direct application of CNS drugs into the diploic space between the outer and inner cortex of the skull, namely, intracalvariosseous administration (ICO). It was successfully demonstrated that small molecular to large colloidal drugs can readily reach the brain after ICO in mice and rabbits. Here, we report that a single ICO of donepezil microspheres protects cognitive impairment in Alzheimer mouse models over a month-long period. Donepezil-loaded long-acting microspheres (DPZ@LAM) were prepared with biodegradable poly(DL-lactide-co-glycolide) (PLGA). Pharmacokinetic study and behavioral test were performed to determine the brain exposure and therapeutic effects after ICO of DPZ@LAM in scopolamine-induced memory-deficient mice. DPZ@LAM were capable of a month-long and precisely controlled drug release. After a single ICO of DPZ@LAM, DPZ concentration in brain sustained above the effective therapeutic levels for four weeks. The long-lasting brain exposure also led to significantly recovered cognitive function in scopolamine-induced memory-deficient mice, along with decreased acetylcholinesterase activity and increased brain-derived neurotrophic factor. ICO allows for BBB-bypassing brain drug delivery through the direct connection between the skull bone marrow and brain, providing an alternative approach for the treatment of neurodegenerative diseases with otherwise BBB impermeable CNS drugs.
最近的研究表明颅骨骨髓、脑膜和大脑之间存在直接联系。为了探索这些联系以便将脑内药物递送至大脑,我们之前提出了将 CNS 药物直接应用于颅骨内外皮层之间的板障空间,即颅腔内给药(intracalvariosseous administration,ICO)。在小鼠和兔模型中成功证明了小分子到大胶体药物在 ICO 后可轻易到达大脑。在此,我们报告称,多奈哌齐微球单次 ICO 可在长达一个月的时间内保护阿尔茨海默病小鼠模型的认知障碍。载有多奈哌齐的长效微球(DPZ@LAM)是用可生物降解的聚(DL-乳酸-共-乙醇酸)(PLGA)制备的。进行了药代动力学研究和行为测试,以确定在东莨菪碱诱导的记忆缺陷小鼠中 ICO 后 DPZ@LAM 的脑暴露和治疗效果。DPZ@LAM 能够进行长达一个月的、精确控制的药物释放。在 DPZ@LAM 单次 ICO 后,脑内 DPZ 浓度持续维持在有效的治疗水平四周以上。长时间的脑暴露还导致东莨菪碱诱导的记忆缺陷小鼠认知功能显著恢复,同时乙酰胆碱酯酶活性降低,脑源性神经营养因子增加。ICO 通过颅骨骨髓和大脑之间的直接联系允许绕过 BBB 的脑内药物递送,为治疗 otherwiseBBB 不可渗透的 CNS 药物的神经退行性疾病提供了一种替代方法。